Please login to the form below

Not currently logged in
Email:
Password:

Merz acquire BioForm Medical

Merz Pharma have agreed to acquire BioForm Medical for $253m, expanding its presence in cosmetic pharmaceuticals

Merz Pharma Group have agreed to acquire BioForm Medical Inc (BFRM) for $253m, expanding its cosmetic pharmaceuticals portfolio. The privately held German pharmaceutical company already has a presence in anti-ageing skincare with their product Belotero - the world's first monophasic hyaluronic acid dermal filler with patented CPM technology.

Merz will pay $5.45 per BioForm share, a 60 per cent premium to the company's Thursday closing price.

BioForm, which went public in late 2007, specialises in injectable drugs to improve the appearance of the skin, including treatment of wrinkles and folds, as well as varicose veins. The company is non profitable, though sales have been improving and last November BioForm narrowed its loss forecast for its fiscal year ending June 30.

6th January 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics